May 16, 2024

Ionis Announces Positive Results from Halos Phase 1/2a

Exciting news for the Angelman syndrome community! Ionis’ Angelman syndrome program, ION582, has just shared positive preliminary results from the Phase 1/2a HALOS clinical trial.  Ionis will be providing an update at the upcoming Angelman Syndrome Foundation meeting in July. […]

Read more
ASA and ASF Working Together
November 17, 2020

Joint Initiative between ASA and ASF

The International Angelman Syndrome Alliance (ASA) and the Angelman Syndrome Foundation (ASF) announced a newly formed joint initiative: the Global Community Advisory Board (CAB). They will work together to represent the Angelman community as a unified voice when engaging with […]

Read more
ladder database logo
November 25, 2019

Ladder Database

A new network platform, Linking Angelman and Dup15q Data for Expanded Research (LADDER), will offer caregivers access to information about a larger population of patients living with Angelman or Dup15 syndromes to better inform their decisions regarding treatments and interventions. […]

Read more
Ovid Therapeutics logo
December 6, 2018

Clinical Trial of OV101 in Pediatric Patients

On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. […]

Read more